Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction
Kenneth W. Mahaffey(Cardiovascular Institute of the South), Christopher B. Granger(Clinical Research Institute), Alejandro Barbagelata(Favaloro Foundation), Raymond J. Gibbons(Mayo Clinic), Victor Molina‐Viamonte(Columbia University), Joseph Puma(Research Triangle Park Foundation), Cesare Orlandi(University of Rochester Medical Center), Robert M. Califf(Duke University), Massoud A. Leesar(University of Louisville), Roger D. Blevins(Research Triangle Park Foundation), Paul R. Eisenberg(Washington University in St. Louis), Kevin F. Browne(Watson Clinic), A.Cecilia Casas(Research Triangle Park Foundation), Marcelo F. DiCarli(Harper University Hospital), Roberto Bolli(University of Louisville Hospital)
Cited by 541
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k